

INFORMATION OF SOPHARMA AD ON FACTS
AND CIRCUMSTANCES WHICH HAVE OCCURRING
AS AT FIRST QUARTER OF 2018
OF SOPHARMA AD

- 1.1. No change in the persons controlling the Company.
- 1.2. (Annulled – State Gazette, issue 63 from 2016).
- 1.3. (Annulled – State Gazette, issue 63 from 2016).
- 1.4. (Annulled – State Gazette, issue 63 from 2016).
- 1.5. (Annulled – State Gazette, issue 63 from 2016).
- 1.6. No opening of bankruptcy proceedings against the company or its subsidiary or any significant events related to production.
- 1.7. No acquisition, use or disposition of high-value assets.
- 1.8. Decision on conclusion, termination and cancellation of joint venture agreements.
- 1.9. (Annulled – State Gazette, issue 82 from 2007).
- 1.10. Change of the Company's Auditors - At the Annual General Meeting of Shareholders of SOPHARMA AD, held on 02.06.2017, the auditor company "BAYKER TILLY KLITOU AND PARTNERS" AD, with headquarters in Sofia, Acad. Ivan Evst. Geshov "№ 104, was elected for the auditing and certifying of the Annual Financial Statement of the Company for 2017.
- 1.11. (Annulled – State Gazette, issue 63 from 2016).
- 1.12. (Annulled – State Gazette, issue 63 from 2016).
- 1.13. (Annulled – State Gazette, issue 63 from 2016).
- 1.14. (Annulled – State Gazette, issue 63 from 2016).
- 1.15. (Annulled – State Gazette, issue 63 from 2016).
- 1.16. (Annulled – State Gazette, issue 63 from 2016).
- 1.17. (Annulled – State Gazette, issue 63 from 2016).
- 1.18. (Annulled – State Gazette, issue 63 from 2016).
- 1.19. (Annulled – State Gazette, issue 63 from 2016).
- 1.20. (Annulled – State Gazette, issue 63 from 2016).
- 1.21. (Annulled – State Gazette, issue 63 from 2016) No conclusion or performance of essential contracts, which do not relate to the ordinary business of the Company.
- 1.22. (Annulled – State Gazette, issue 63 from 2016).
- 1.23. (Annulled – State Gazette, issue 63 from 2016).
- 1.24. (Annulled – State Gazette, issue 63 from 2016).
- 1.25. (Annulled – State Gazette, issue 63 from 2016).
- 1.26. (Annulled – State Gazette, issue 63 from 2016).
- 1.27. (Annulled – State Gazette, issue 63 from 2016).
- 1.28. (Annulled – State Gazette, issue 63 from 2016).

1.29. (Annulled – State Gazette, issue 63 from 2016).

1.30. There is no opening or termination of a court or arbitration case relating to the debts or claims of the company or its subsidiary with a claim price of at least 10 % of the company's equity.

1.31. No purchase, sale or pledge of shareholdings in companies by the issuer or its subsidiary in the first quarter of 2018.

1.32. (Annulled – State Gazette, issue 63 from 2016).

1.33. (Annulled – State Gazette, issue 63 from 2016).

1.34. Other circumstances that the Company considers may be relevant to investors in taking a decision to acquire, sell or continue to hold publicly-traded securities:

On 30 January 2018, the company received a notification for disclosure of a shareholding under Art. 145 of the Public Offering of Securities Act (POSA), for the sale of 250,000 shares, representing 0.19%, with which the share participation of ZUPF "Allianz Bulgaria" in the capital of Sopharma AD reached 4.99%.

On 23.02.2018 an Extraordinary General Meeting of Shareholders of Sopharma AD took place.

At the General Meeting a decision was taken for the transformation by merger of Unipharm AD, UIC: 831537465, in Sopharma AD, UIC: 831902088. As a result of the merger, the whole property of Unipharm AD, UIC 831537465, will be transferred to Sopharma AD, UIC 831902088 under the conditions of general succession.

The General Meeting approved a Contract for the transformation by merger of Unipharm AD, UIC 831537465 in Sopharma AD, UIC 831902088, concluded on 14 September 2017 and of Annex №1 of 08 November 2017 to it.

The General Meeting approved the Report of the Board of Directors of Sopharma AD to the shareholders of the company regarding the transformation by merger of Unipharm AD into Sopharma AD.

The General Meeting approved the Auditor's Report under Art. 262m of the CA on the transformation by merger of Unipharm AD into Sopharma AD.

The General Meeting approves amendments to the Articles of Association of the Company which allow the payment of an interim dividend on the basis of a 6-month financial report pursuant to the Public Offering of Securities Act.

The General Meeting adopted a resolution for the redemption of own shares under the following conditions: up to 10% of the total number of shares issued by the Company but no more than 3% in each calendar year; term of the redemption - no longer than 5 (five) years; minimum redemption price - not less than the nominal value per share of the company's capital; maximum redemption price - BGN 5.50 per share.

Sopharma AD informs all interested parties that the interim financial statements of the Company as at 31 March 2018 have not been verified by a registered auditor.

Ognian Donev
Executive director